Part 2/6:
Following the FDA's approval in September 2023, Neuralink has conducted tests on just three individuals so far. While some restoration of functionality has been reported in one case, the journey has not been without complications. For instance, issues arose when wires within one implant retracted, diminishing the chip's ability to decode brain signals. To address this, adjustments were necessary in the algorithms utilized by the device.